TY - CHAP
T1 - Hematologic cancer survivorship management
T2 - Lymphoma
AU - Rodriguez, Maria Alma
AU - Ballas, Leslie
AU - Simar, Kristin
N1 - Publisher Copyright:
© The University of Texas M.D. Anderson Cancer Center 2015.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Lymphoid malignancies are a family of diverse cancers arising in the cells of the immune system. Lymphoid leukemia, lymphoma, and myeloma belong to this category of cancers. This chapter will focus on lymphomas and the late effects of treatment. Lymphomas are broadly categorized into Hodgkin lymphomas, which are uncommon, and non-Hodgkin lymphomas, which are the sixth most common malignancy in men and women. Incidence of non-Hodgkin lymphoma appears to be rising, although the reasons for this are unclear. Treatment for lymphoma has improved substantially over the past 50 years, resulting in a large population of long-term lymphoma survivors. Patients with lymphoma are treated principally with chemotherapy, immunotherapy, radiation, or stem cell transplantation. Surgery generally does not have a role in the treatment of these disorders except in rare cases. Different treatment modalities have different late side effects. In this chapter, we will summarize the most commonly known potential late effects of chemotherapeutic agents and radiation, the few situations in which surgery is used and its long-term effects, and recommended practice for surveillance of recurrence and late effects.
AB - Lymphoid malignancies are a family of diverse cancers arising in the cells of the immune system. Lymphoid leukemia, lymphoma, and myeloma belong to this category of cancers. This chapter will focus on lymphomas and the late effects of treatment. Lymphomas are broadly categorized into Hodgkin lymphomas, which are uncommon, and non-Hodgkin lymphomas, which are the sixth most common malignancy in men and women. Incidence of non-Hodgkin lymphoma appears to be rising, although the reasons for this are unclear. Treatment for lymphoma has improved substantially over the past 50 years, resulting in a large population of long-term lymphoma survivors. Patients with lymphoma are treated principally with chemotherapy, immunotherapy, radiation, or stem cell transplantation. Surgery generally does not have a role in the treatment of these disorders except in rare cases. Different treatment modalities have different late side effects. In this chapter, we will summarize the most commonly known potential late effects of chemotherapeutic agents and radiation, the few situations in which surgery is used and its long-term effects, and recommended practice for surveillance of recurrence and late effects.
UR - http://www.scopus.com/inward/record.url?scp=84944616534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944616534&partnerID=8YFLogxK
U2 - 10.1007/978-1-4939-0986-5_12
DO - 10.1007/978-1-4939-0986-5_12
M3 - Chapter
AN - SCOPUS:84944616534
SN - 9781493909858
SP - 201
EP - 218
BT - Advances in Cancer Survivorship Management
PB - Springer New York
ER -